| Ident. | Authors (with country if any) | Title |
|---|
| 000225 |
Graeme J. Hankey [Australie] ; Susanna R. Stevens [États-Unis] ; Jonathan P. Piccini [États-Unis] ; Yuliya Lokhnygina [États-Unis] ; Kenneth W. Mahaffey [États-Unis] ; Jonathan L. Halperin [États-Unis] ; Manesh R. Patel [États-Unis] ; Günter Breithardt [Allemagne] ; Daniel E. Singer [États-Unis] ; Richard C. Becker [États-Unis] ; Scott D. Berkowitz [États-Unis] ; John F. Paolini [France] ; Christopher C. Nessel [États-Unis] ; Werner Hacke [Allemagne] ; Keith A. A. Fox [Royaume-Uni] ; Robert M. Califf [États-Unis] | Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation |
| 000393 |
Pierre Amarenco [France] ; Stephen Davis [Australie] ; Elizabeth F. Jones [Australie] ; Ariel A. Cohen [France] ; Wolf-Dieter Heiss [Allemagne] ; Markku Kaste [Finlande] ; Cédric Laouenan [France] ; Dennis Young [Australie] ; Malcolm Macleod [Australie, Royaume-Uni] ; Geoffrey A. Donnan [Australie] | Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques |
| 001167 |
Harry R. Büller [Pays-Bas] ; Alex S. Gallus [Australie] ; Gerard Pillion [France] ; Martin H. Prins [Pays-Bas] ; Gary E. Raskob [États-Unis] | Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial |
| 002473 |
Graeme J. Hankey [Australie] ; Werner Hacke [Allemagne] ; J. Donald Easton [États-Unis] ; S. Claiborne Johnston [États-Unis] ; Jean-Louis Mas [France] ; Danielle M. Brennan [États-Unis] ; Deepak L. Bhatt [États-Unis] ; Keith A. A. Fox [Royaume-Uni] ; Eric J. Topol [États-Unis] | Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients: A Prespecified Substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Trial |
| 002C84 |
Steven R. Steinhubl [États-Unis, Suisse, France, Australie, Canada] ; Deepak L. Bhatt ; Danielle M. Brennan ; Gilles Montalescot ; Graeme J. Hankey ; John W. Eikelboom ; Peter B. Berger ; Eric J. Topol | Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding |
| 003B87 |
Mark L. Kahn [États-Unis, Australie, France] ; Pierre Mangin ; Cindy L. Yap ; Christelle Nonne ; Sharelle A. Sturgeon ; Isaac Goncalves ; YUPING YUAN ; Simone M. Schoenwaelder ; Christine E. Wright ; Francois Lanza ; Shaun P. Jackson | Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRγ deficiency. Commentary |
| 004B42 |
Harry R. Büller [Pays-Bas, États-Unis, France, Australie, Canada, Italie] ; Bruce L. Davidson ; Hervé Decousus ; Alexander Gallus ; Michael Gent ; Franco Piovella ; Martin H. Prins ; Gary Raskob ; Annelise E. M. Segers ; Roger Cariou ; Oscar Leeuwenkamp ; Anthonie W. A. Lensing | Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis |
